American International Group Inc. held its position in Core Laboratories N.V. (NYSE:CLB) during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 3,430 shares of the oil and gas company’s stock at the end of the first quarter. American International Group Inc.’s holdings in Core Laboratories N.V. were worth $396,000 at the end of the most recent reporting period.
Other institutional investors have also bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in Core Laboratories N.V. by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 217,670 shares of the oil and gas company’s stock valued at $26,128,000 after buying an additional 6,962 shares during the last quarter. Guggenheim Capital LLC increased its position in Core Laboratories N.V. by 36.0% in the fourth quarter. Guggenheim Capital LLC now owns 13,752 shares of the oil and gas company’s stock valued at $1,651,000 after buying an additional 3,640 shares during the last quarter. Norges Bank acquired a new position in Core Laboratories N.V. during the fourth quarter valued at $31,248,000. UBS Asset Management Americas Inc. increased its position in Core Laboratories N.V. by 0.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 114,731 shares of the oil and gas company’s stock valued at $13,772,000 after buying an additional 556 shares during the last quarter. Finally, Integrated Investment Consultants LLC increased its position in Core Laboratories N.V. by 0.8% in the first quarter. Integrated Investment Consultants LLC now owns 2,330 shares of the oil and gas company’s stock valued at $269,000 after buying an additional 19 shares during the last quarter.
Core Laboratories N.V. (NYSE CLB) opened at 106.91 on Tuesday. The company’s 50-day moving average is $103.76 and its 200 day moving average is $112.86. Core Laboratories N.V. has a 52 week low of $96.30 and a 52 week high of $127.82. The stock has a market cap of $4.72 billion, a PE ratio of 70.80 and a beta of 1.60.
Core Laboratories N.V. (NYSE:CLB) last released its earnings results on Wednesday, April 19th. The oil and gas company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.03. Core Laboratories N.V. had a net margin of 11.10% and a return on equity of 43.28%. The company had revenue of $157.81 million for the quarter, compared to analysts’ expectations of $150.44 million. During the same quarter last year, the business earned $0.37 EPS. The firm’s revenue was up 2.7% compared to the same quarter last year. On average, analysts expect that Core Laboratories N.V. will post $2.19 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, August 14th. Shareholders of record on Monday, July 17th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.06%. The ex-dividend date is Thursday, July 13th. Core Laboratories N.V.’s payout ratio is 145.70%.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/07/18/core-laboratories-n-v-nyseclb-stake-maintained-by-american-international-group-inc.html.
Several equities analysts have recently weighed in on CLB shares. Scotiabank set a $133.00 target price on shares of Core Laboratories N.V. and gave the stock a “hold” rating in a research note on Wednesday, March 22nd. Tudor Pickering started coverage on shares of Core Laboratories N.V. in a research note on Thursday, March 23rd. They issued a “hold” rating for the company. Zacks Investment Research downgraded shares of Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research note on Tuesday, April 11th. Loop Capital upgraded shares of Core Laboratories N.V. from a “hold” rating to a “buy” rating and lifted their target price for the stock from $125.00 to $130.00 in a research note on Friday, April 21st. Finally, ABN Amro upgraded shares of Core Laboratories N.V. to a “hold” rating in a research note on Friday, April 21st. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $122.36.
Core Laboratories N.V. Company Profile
Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.
Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.